ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Clinical Staging of Patients with Early Esophageal Adenocarcinoma: Does FDG-PET/CT Have a Role?

Monday, July 28, 2014

Submitted by

Mark Ferguson

Source

Source Name: Journal of Thoracic Oncology

Source URL: http://journals.lww.com/jto/Abstract/2014/08000/Clinical_Staging_of_Patients_wit…

Author(s)

Cuellar, Sonia L. Betancourt; Carter, Brett W.; Macapinlac, Homer A.; Ajani, Jaffer A.; Komaki, Ritsuko; Welsh, James W.; Lee, Jeffrey H.; Swisher, Stephen G.; Correa, Arlene M.; Erasmus, Jeremy J.; Hofstetter, Wayne L.

The authors queried whether PET has utility in clinically staging Tis or T1 esophageal cancers; this was a single institution retrospective study involving 79 pts. The incidence of FDG uptake increased with increasing T status, as did the SUV. Nodal staging was false positive in 3 pts and false negative all 13 pts with nodal involvement. Metastatic staging was false positive in 5 pts. PET is not recommended for pts with Tis or T1 disease on EUS.